123 related articles for article (PubMed ID: 30124539)
1. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
Kenessey I; Kramer Z; István L; Cserepes MT; Garay T; Hegedűs B; Dobos J; Tímár J; Tóvári J
Melanoma Res; 2018 Dec; 28(6):536-546. PubMed ID: 30124539
[TBL] [Abstract][Full Text] [Related]
2. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
5. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
6. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
Zhao B; Cheng X; Zhou X
Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
[TBL] [Abstract][Full Text] [Related]
7. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.
Gross A; Niemetz-Rahn A; Nonnenmacher A; Tucholski J; Keilholz U; Fusi A
Target Oncol; 2015 Mar; 10(1):77-84. PubMed ID: 24824730
[TBL] [Abstract][Full Text] [Related]
8. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway.
Chiu YJ; Yang JS; Tsai FJ; Chiu HY; Juan YN; Lo YH; Chiang JH
Environ Toxicol; 2022 Apr; 37(4):868-879. PubMed ID: 34994998
[TBL] [Abstract][Full Text] [Related]
10. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
12. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
13. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
Ji Z; Njauw CN; Guhan S; Kumar R; Reddy B; Rajadurai A; Flaherty K; Tsao H
J Invest Dermatol; 2021 May; 141(5):1317-1324.e1. PubMed ID: 33159968
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
17. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
18.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
19. Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance.
Pastwińska J; Karaś K; Karwaciak I; Ratajewski M
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188754. PubMed ID: 35772580
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]